A VAC (sometimes called a New Product Committee or Technology Assessment Committee) brings together clinicians, supply chain, finance, and quality to evaluate the clinical evidence, cost, integration burden, and supply considerations of proposed new products. Requests usually start with a clinician sponsor and a standard form covering clinical evidence, cost per case, contract impact, training needs and IT or sterile processing burden. Committees often meet monthly and may approve a product, reject it, or allow a time-limited trial. Companies that bring peer-reviewed outcomes, an economic model and a clear coding and payment story tend to move through faster.

Why it matters

VAC approval is often the gating step for hospital adoption. Effective VAC submissions combine clinical evidence, total cost of care impact, and operational readiness materials.

Common pitfalls

•Failing to provide clear, concise evidence of regulatory clearances or approvals can delay VAC review.
•Overlooking the importance of cybersecurity documentation, especially for connected devices, can be a major VAC hurdle.
•Submitting outdated or non-relevant clinical evidence will undermine a product's credibility with the VAC.
•Not understanding the specific evidence requirements of each hospital system's VAC can lead to repeated submissions and delays.
•Ignoring the total cost of ownership, including training, maintenance, and disposables, can lead to VAC rejection despite clinical benefits.

Sources

AHRMM Value Analysis · AHRMM
AdvaMed Code of Ethics · AdvaMed

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.